Skip to main content
. 2019 May 25;393(10186):2125–2134. doi: 10.1016/S0140-6736(19)30724-X

Table 4.

Adverse events

Levetiracetam (n=132)
Phenytoin (n=130)
Both drugs (n=24)
Total (n=286)
Events Patients Events Patients Events Patients Events Patients
Any adverse event 20 16 (12%) 23 18 (14%) 8 4 (17%) 51 38 (13%)
Agitation 11 11 (8%) 4 4 (3%) 0 0 15 15 (5%)
Hypotension 2 2 (2%) 3 3 (2%) 1 1 (4%) 6 6 (2%)
Catheter site related 1 1 (<1%) 1 1 (<1%) 3 2 (8%) 5 4 (1%)
Extravasation 0 0 4 4 (3%) 1 1 (4%) 5 5 (2%)
Tachycardia 1 1 (<1%) 3 3 (2%) 1 1 (4%) 5 5 (2%)
Rash 2 2 (2%) 1 1 (<1%) 0 0 3 3 (1%)
Hypertension 0 0 2 2 (2%) 0 0 2 2 (<1%)
Reaction to ceftriaxone 0 0 0 0 1 1 (4%) 1 1 (<1%)
Confusion 1 1 (<1%) 0 0 0 0 1 1 (<1%)
Decreased consciousness 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Hallucination 1 1 (<1%) 0 0 0 0 1 1 (<1%)
Infusion site erythema 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Mechanical ventilation complication 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Pallor 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Stridor 0 0 0 0 1 1 (4%) 1 1 (<1%)
Vomiting 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Wheezing 1 1 (<1%) 0 0 0 0 1 1 (<1%)